Scinai Immunotherapeutics (SCNI) Operating Expenses (2015 - 2026)

Scinai Immunotherapeutics has disclosed Operating Expenses across 12 years of filings, most recently posting -$894000.0 for Q2 2026.

• In Q2 2026, Operating Expenses fell 28.26% year-over-year to -$894000.0; the TTM figure through Jun 2026 stood at -$4.7 million (up 29.94% YoY), while the FY2025 annual figure was -$5.4 million, up 32.85% from the prior year.
• Operating Expenses came in at -$894000.0 for Q2 2026 at Scinai Immunotherapeutics, up from -$1.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $10.8 million in Q2 2022 to a low of -$5.7 million in Q2 2024.
• Average Operating Expenses over 5 years is -$347125.0, with a median of -$1.6 million recorded in 2025.
• Year-over-year, Operating Expenses sank 320.39% in 2024 and jumped 87.81% in 2025.
• Over 5 years, Operating Expenses stood at -$4.1 million in 2022, then jumped by 55.96% to -$1.8 million in 2023, then decreased by 14.98% to -$2.1 million in 2024, then jumped by 66.75% to -$697000.0 in 2025, then declined by 28.26% to -$894000.0 in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were -$894000.0 in Q2 2026, -$1.3 million in Q1 2026, and -$697000.0 in Q2 2025.